{"name":"Azienda Ospedaliera di Padova","slug":"azienda-ospedaliera-di-padova","ticker":"","exchange":"","domain":"","description":"Azienda Ospedaliera di Padova is a leading healthcare provider in Italy, focusing on clinical care, research, and education. The institution is involved in the development and marketing of several drugs, contributing to advancements in patient care.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"dexmedetomidine (IN)","genericName":"dexmedetomidine (IN)","slug":"dexmedetomidine-in","indication":"Sedation of intubated and mechanically ventilated patients in intensive care units","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"peginterferon plus ribavirin","genericName":"peginterferon plus ribavirin","slug":"peginterferon-plus-ribavirin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"dexmedetomidine (IN)","genericName":"dexmedetomidine (IN)","slug":"dexmedetomidine-in","phase":"marketed","mechanism":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.","indications":["Sedation of intubated and mechanically ventilated patients in intensive care units","Sedation and analgesia for procedural sedation and anesthesia","Perioperative anxiolysis and analgesia"],"catalyst":""},{"name":"peginterferon plus ribavirin","genericName":"peginterferon plus ribavirin","slug":"peginterferon-plus-ribavirin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA4QWtINWlWRXR1UFBFR19XZ3BIYjNIaElfaUp4aXpnbHZ3SDQzMnVLYzVZU0hicVNZZ2RpVEM3RllQTnhGU0RZaE1hVUx2OWR4YlBPQ19pYVo4WjVyQ2tz?oc=5","date":"2025-07-01","type":"trial","source":"Nature","summary":"BRIDGE: a multi-stakeholder workstream focused on assessing new clinical endpoints in ophthalmology clinical trials [Building Research Innovations and Developing Global Endpoints] | Eye - Nature","headline":"BRIDGE: a multi-stakeholder workstream focused on assessing new clinical endpoints in ophthalmology clinical trials [Bui","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5veWFUY1UzVF9PNUJsRDNfS05GZWt2UkZGdjFISUxvd0dsZDJRUjVSVHJxbTlsUGZZQzZvOW9SLUtYekM2SzRIVVpBQkVsVGhLVk1ockZfeXVIX2Jtd2gwNmZ2dUFmTWVPNEdn?oc=5","date":"2025-06-21","type":"pipeline","source":"Wiley Online Library","summary":"Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder? - Wiley Online Library","headline":"Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBnRXFNczVBYy0wd3dGXzFrOHRZUHI1Vi1wZE0wWmpTaFVuNmx3TVdoRzYzWV82VTNFOXYwZkhHWHNTR0k5QWFldklHemMyWXlfbldwVXJ3WVFUeURveEd2R2lBdWRleVg3TFE?oc=5","date":"2024-10-29","type":"pipeline","source":"Wiley Online Library","summary":"Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease - Wiley Online Library","headline":"Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1IWW1VRm5WZURDRHg5cElHSFcyc21XQnV0ci11VXZJM1lUdUhzbFNTbTBMdFFLdkRzSmFXc3drVzduczAtLXNQMVJDdzdYOHlKVjJkN2k5ZFNlT2tSVTk0?oc=5","date":"2023-08-17","type":"trial","source":"Nature","summary":"Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis - Nature","headline":"Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}